Actively Recruiting
Evaluation of Deucravacitinib Combined with Anti-TNF Therapy for Adults with Difficult-to-Control Psoriatic Arthritis
Led by University of Texas Southwestern Medical Center · Updated on 2026-09-01
128
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of adding deucravacitinib to the current treatment of adults with psoriatic arthritis PsA to see if it improves symptoms and quality of life. This study focuses on a new approach that targets different parts of psoriatic disease, aiming to provide better symptom relief with possibly fewer or more manageable side effects than some existing therapies. Participants will receive either deucravacitinib tablets combined with their established anti-TNF injection therapy or placebo tablets with anti-TNF injections. The study compares these two groups to assess the impact of the combination treatment. Treatments are given alongside stable background medications like csDMARDs, NSAIDs, or oral glucocorticoids when applicable. During the study, participants will undergo assessments at various time points up to 48 weeks, including evaluations of skin and joint symptoms, disease activity, safety through adverse event monitoring, and quality of life measures. Researchers will measure outcomes such as the proportion of patients achieving low disease activity and changes in pain, itching, and physical function. The total study duration spans up to 48 weeks with scheduled visits for monitoring treatment effects and safety.
CONDITIONS
Brief Title
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Research Team
A
Aleuna Lee, PhD, CCRC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here